Related Experiment Video
Updated: Jun 6, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Preclinical approaches to study the biology and treatment of brain metastases
William Cruz-Muñoz1, Robert S Kerbel
1Sunnybrook Health Sciences Centre, Molecular and Cellular Biology Research, S-217, 2075 Bayview Ave., Toronto, Ontario M4N 3M5, Canada.
Abstract:
Metastatic spread to the central nervous system (CNS) is a common and devastating manifestation of major cancer types. Its incidence is associated with poor prognosis manifested by neurological deterioration leading to diminished quality of life and an extremely short median survival. CNS metastasis is becoming an increasingly important clinical problem. This is especially the case for certain types of cancers for which effective treatments of visceral disease are available. As a result of the present limitations in treating CNS metastases, this manifestation of tumor progression remains an unmet clinical need. Despite its significance, our general understanding of the mechanisms that regulate the brain-metastatic phenotype is currently meager. Both the analysis of mechanistic aspects of brain metastasis and the development of effective treatments necessitate the use of appropriate in vivo models that recapitulate the interaction of the tumor cells with the microenvironment of the brain. Here we review the available preclinical models of CNS metastasis and their use as tools to advance knowledge of the biology of the disease (with the aim of identifying relevant molecular determinants, prognostic biomarkers, and therapeutic targets) as well as examining effective approaches for treatment.
Insights
Brain metastasis, or spread to the central nervous system (CNS), is a severe cancer complication with poor outcomes. Understanding brain metastasis mechanisms and developing treatments requires effective preclinical models.
Area of Science:
- Oncology
- Neuroscience
- Cancer Biology
Background:
- Central nervous system (CNS) metastases are a common, devastating complication of many cancers, leading to poor prognosis and reduced quality of life.
- The increasing incidence of CNS metastases, especially in cancers with effective systemic treatments, highlights an unmet clinical need.
- Current understanding of the molecular mechanisms driving brain metastasis is limited, hindering the development of effective therapies.
Purpose of the Study:
- To review existing preclinical models for studying CNS metastasis.
- To evaluate the utility of these models in advancing the understanding of brain metastasis biology.
- To identify potential molecular determinants, prognostic biomarkers, and therapeutic targets for CNS metastases.
Main Methods:
- Review of preclinical in vivo models of CNS metastasis.
- Analysis of how these models recapitulate tumor cell interactions within the brain microenvironment.
- Examination of current and potential therapeutic strategies for CNS metastases.
Main Results:
- Preclinical models are crucial for studying the mechanisms of brain metastasis.
- These models aid in identifying molecular drivers and biomarkers for CNS metastases.
- The review highlights the need for improved therapeutic approaches.
Conclusions:
- Effective preclinical models are essential for dissecting the biology of brain metastasis.
- Advancing knowledge through these models can lead to better prognostic biomarkers and therapeutic targets.
- Addressing the unmet clinical need in CNS metastases requires continued research using appropriate in vivo systems.
